[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@easym_test "Current Evidence for MRD Adapted Therapy in Multiple Myeloma 📢 There is no denying that Minimal Residual Disease (MRD) is a strong prognostic factor. The question on everyones mind is whether or not it can help guide clinical decision making. Recent clinical trials including MASTER Elo-KRD and Myeloma XI show evidence on how MRD can help. 💡 Why it matters: MRD is moving from a research metric to a real world tool that personalizes care reduces treatment burden and improves quality of life for patients with multiple myeloma. Find more info here: #MultipleMyeloma #MRD #CancerResearch"
X Link @easym_test 2025-11-03T15:00Z XXX followers, XX engagements

"🚨 ASH 2025 Abstracts are Live Were excited to share EasyMs latest research in Multiple Myeloma: 📄10587: Tracking Peripheral Residual Disease in Myeloma: Clonotypic Sequencing and Mass Spectrometry in the Teclistamab Era - 📄15025: Sensitive Peripheral Residual Disease (PRD) Detection Using Clonotypic Mass Spectrometry (EasyM) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Check out the abstracts and plan to visit us at ASH to learn more. #IMS2025 #MultipleMyeloma #MRD #mmsm #MassSpectrometry #EasyM #MyelomaResearch @ASH_hematology"
X Link @easym_test 2025-11-04T15:21Z XXX followers, XX engagements